Neuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.
Follow NEUP
Neuphoria Therapeutics Inc. (NEUP) Altman Z-score
Neuphoria Therapeutics Inc.'s Altman Z-score for fiscal 2026 is −7.55, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −7.55 | (0.41) |
| FY2025 | −7.14 | 1.27 |
| FY2023 | −8.42 | (9.48) |
| FY2022 | 1.06 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.71 | — | 0.85 | |
| Retained earnings / total assets | (6.68) | — | −9.35 | |
| EBIT / total assets | (0.57) | — | −1.89 | |
| Market value of equity / total liabilities | 4.68 | — | 2.81 | |
| Sales / total assets | 0.04 | — | 0.04 | |
| Altman Z-score | Distress zone | −7.55 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −14.70 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| TCRX TScan Therapeutics, Inc. compare | −3.5× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | −6.7× |
| NEUP Neuphoria Therapeutics Inc. | −7.5× |
| ATYR aTyr Pharma, Inc. compare | −9.3× |
| DYAI Dyadic International Inc. compare | −12.4× |
| JSPR Jasper Therapeutics, Inc. compare | — |
| ACGN Aceragen, Inc. compare | — |
| ANEB Anebulo Pharmaceuticals, Inc. compare | — |
| PBM Psyence Biomedical Ltd. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets